Bristol Myers Squibb’s Abecma Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan Read more
FDA Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Read more
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer Read more
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck Read more
Vanda Pharmaceuticals Announces that FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis Read more
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment Read more
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio Read more
Novavax’s Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization Read more